(Total Views: 712)
Posted On: 07/20/2022 3:21:18 PM
Post# of 153996
fierce biotech re gsk
"GlaxoSmithKline is scrapping more than 30 drug development programs. The major cull of pipeline prospects will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space.
Emma Walmsley unveiled the overhaul of GSK’s R&D priorities at the end of her first full quarter as CEO. Walmsley is focusing GSK’s attention on two therapeutic areas in which it already has a sizable presence—respiratory and HIV/infectious diseases—and two in which it aspires to grow—oncology and immuno-inflammation. GSK will spend 80% of its R&D budget on top prospects in these areas."
"GlaxoSmithKline is scrapping more than 30 drug development programs. The major cull of pipeline prospects will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space.
Emma Walmsley unveiled the overhaul of GSK’s R&D priorities at the end of her first full quarter as CEO. Walmsley is focusing GSK’s attention on two therapeutic areas in which it already has a sizable presence—respiratory and HIV/infectious diseases—and two in which it aspires to grow—oncology and immuno-inflammation. GSK will spend 80% of its R&D budget on top prospects in these areas."
(2)
(0)
